Cytosorbents Aktie [WKN DE: A12GDU / ISIN: US23283X2062]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Cytosorbents Corp

15.02.18		CytoSorbents Expands Its Partnership with Biocon to Launch CytoSorb® in Malaysia (PR Newswire)
06.02.18		CytoSorbents to Present at the 20th Annual BIO CEO & Investor Conference (PR Newswire)
01.02.18		New Study Demonstrates Improved Hemodynamic Stability After Heart Transplant Surgery using Intraoperative CytoSorb® Blood Purification (PR Newswire)
19.01.18		ProfNet Experts Available on Travel, Eating Clean, Reducing Stress, More (PR Newswire)
08.01.18		CytoSorbents Pre-Announces Preliminary Fourth Quarter and Full Year 2017 Results and Issues Stockholder Letter (PR Newswire)
03.01.18		CytoSorbents To Provide Corporate Update at Biotech Showcase 2018 (PR Newswire)
21.12.17		CytoSorbents Achieves Key Milestone with FDA Approval of the U.S. REFRESH 2 Pivotal Cardiac Surgery Trial IDE Application (PR Newswire)
20.12.17		Cohen & Steers Infrastructure Fund, Inc. (UTF) Declares Year-End Capital Gain Distribution (PR Newswire)
19.12.17		CytoSorbents Receives $676,739 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program (PR Newswire)
11.12.17		German Federal Ministry of Education and Research to Fund the CytoSorb® Endocarditis REMOVE Trial (PR Newswire)
29.11.17		CytoSorbents to Present at the LD Micro Main Event Investor Conference (PR Newswire)
09.11.17		CytoSorbents Continues Strong Trajectory of Growth in the Third Quarter 2017 (PR Newswire)
09.11.17		CytoSorbents Recognized on Deloitte's 2017 Technology Fast 500™ as One of the Fastest Growing Companies in North America (PR Newswire)
02.11.17		CytoSorbents to Report Q3 2017 Operating and Financial Results (PR Newswire)
01.11.17		CytoSorbents Awarded Approximately $1.0 Million in Phase II SBIR Funding to Optimize New Treatment Approaches for Severe Hyperkalemia (PR Newswire)
19.10.17		CytoSorb® Usage During Valve Replacement Surgery for Infective Endocarditis Helps Stabilize Patients and May Improve Survival (PR Newswire)
10.10.17		CytoSorbents to Present at the 2017 BIO Investor Forum (PR Newswire)
26.09.17		CytoSorbents Introduces the CytoSorb Therapeutic ECMO™ Kit at the 2017 European Society of Intensive Care Medicine Congress (PR Newswire)
25.09.17		Key Clinical Study Showing Reversal of Refractory Septic Shock in Patients Treated with CytoSorb® (PR Newswire)
14.09.17		World Sepsis Day 2017: CytoSorbents Sponsors the Sepsis Update 2017 Congress and Sepsis Heroes Ceremony (PR Newswire)
11.09.17		Aferetica and CytoSorbents Partner to Enhance the Success of Solid Organ Transplantation (PR Newswire)
06.09.17		CytoSorbents to Present at the 2017 Rodman & Renshaw Annual Global Investment Conference (PR Newswire)
05.09.17		CytoSorbents Highlights Important Research Advances in Traumatic Brain Injury, Hemorrhagic Shock, and Severe Hyperkalemia at the Military Health System Research Symposium (PR Newswire)
14.08.17		CytoSorbents Awarded $719,000 Grant To Acutely Stabilize Severe Burn Patients (PR Newswire)
07.08.17		CytoSorbents Reports Record Quarterly Total Revenue and Product Sales in the Second Quarter 2017 (PR Newswire)
02.08.17		Frost & Sullivan Lauds CytoSorbents for Leading the Critical Care Immunotherapy Segment with its Novel Blood Purification Solution, CytoSorb® (PR Newswire)
02.08.17		Frost & Sullivan Lauds CytoSorbents for Leading the Critical Care Immunotherapy Segment with its Novel Blood Purification Solution, CytoSorb® (PR Newswire)
02.08.17		Frost & Sullivan Lauds CytoSorbents for Leading the Critical Care Immunotherapy Segment with its Novel Blood Purification Solution, CytoSorb® (PR Newswire)
01.08.17		CytoSorbents to Report Q2 2017 Operating and Financial Results (PR Newswire)
27.07.17		AllianceBernstein Holding L.P. Announces Second Quarter Results (PR Newswire)
17.07.17		CytoSorbents Expands Distribution and Sales of CytoSorb® to treat Deadly Inflammation in Panama with DRGR (PR Newswire)
13.07.17		CytoSorbents Awarded $1 Million STTR Phase II Contract To Advance Development of Life-Saving Universal Plasma (PR Newswire)
05.07.17		CytoSorbents Receives Additional $5 Million in Non-Dilutive Debt Financing from Bridge Bank (PR Newswire)
28.06.17		ABI Research Survey Finds More than 50% of Government Respondents Call for Public Technology Management at the Local Level (PR Newswire)
15.06.17		CytoSorbents Announces Director and Management Open Market Stock Purchases (PR Newswire)
06.06.17		CytoSorbents - A Leader in Blood Purification to Treat Deadly Inflammation - Teams with Investor Relations Firm LifeSci Advisors (PR Newswire)
30.05.17		Dr. Eric G. Mortensen, M.D., Ph.D., Clinical Trial Veteran, Joins CytoSorbents as Chief Medical Officer (PR Newswire)
24.05.17		CytoSorbents Selected to Present at Special Operations SOMSA 2017 Conference and 18th Annual B. Riley & Co. Investor Conference (PR Newswire)
22.05.17		Aferetica and CytoSorbents Extend Exclusive "Life-saving" Partnership through 2021 (PR Newswire)
09.05.17		Concierge Auctions Reveals Its International May/June 2017 Lineup Featuring 17 One-Of-A-Kind Properties (PR Newswire)
08.05.17		CytoSorbents Reports First Quarter 2017 Financial Results (PR Newswire)
07.05.17		TXMD All Set For D-day, IMMU Soars On Strategic Plan, CTSO On Watch (RTTNews)
24.04.17		CytoSorbents Awarded $1M Phase II SBIR Contract by U.S. Department of Defense to Advance Fungal Mycotoxin Blood Purification (PR Newswire)
19.04.17		CytoSorbents 2017 - Propelling the Company to the "Next Level" (PR Newswire)
03.04.17		BioDirection Announces Results from Pre-Clinical Study of Tbit™ System for Detection of Traumatic Brain Injury (PR Newswire)
30.03.17		CytoSorbents Announces Proposed Offering of Common Stock (PR Newswire)
28.03.17		CytoSorbents Strengthens Intellectual Property Portfolio with New Patents Issued in the U.S., China, Japan, Russia, and Australia (PR Newswire)
27.03.17		CytoSorbents REFRESH I Trial Abstract Selected for Podium Presentation at the American Association for Thoracic Surgery Centennial Conference (PR Newswire)
22.03.17		Dr. Carl H. June, Cancer Immunotherapy Pioneer, Joins CytoSorbents Scientific Advisory Board (PR Newswire)
20.03.17		CytoSorb® Treatment of HLH - The Parallel to Cytokine Release Syndrome in Cancer Immunotherapy (PR Newswire)

Zurück | 1 | 2 | 3 | Weiter

Newssuche

Meistgelesene Nachrichten

Experte schlägt Alarm: Platzt die Tesla-Blase schneller als gedacht?

Bitcoin & Co.: "Dr. Doom" Roubini prognostiziert Krypto-Blase und warnt Anleger

NVIDIA vor Zahlen: Bank of America sieht Mega-Potenzial

Ripple Kurs Prognose: 10 US-Dollar bereits in wenigen Wochen?

Raiffeisen-Aktie sinkt deutlich: Bank Austria und RBI stellen Kunden bis Ende 2025 um

DAX 40-Titel Rheinmetall-Aktie: So viel Gewinn hätte eine Rheinmetall-Investition von vor 10 Jahren eingebracht

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	21.02.2025 18:25
Kaufwert:	EUR
	Hinzufügen Speichern